Rachel Williams
Family · Sebring, FLNPI 1114523263
Payments from drug & device makers
Across 118 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$337
- Bayer$247
- Ironshore Pharmaceuticals Inc.$209
- Exact Sciences$182
- Lilly USA, LLC$127
- Vanda Pharmaceuticals Inc.$126
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,438100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 16 | $337 |
| Bayer | 10 | $247 |
| Ironshore Pharmaceuticals Inc. | 10 | $209 |
| Exact Sciences | 9 | $182 |
| Lilly USA, LLC | 7 | $127 |
| Vanda Pharmaceuticals Inc. | 6 | $126 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $124 |
| Amgen | 5 | $92 |
| Collegium Pharmaceutical, Inc. | 5 | $87 |
| Novo Nordisk | 4 | $85 |
| Tris Pharma Inc | 5 | $79 |
| Paratek Pharmaceuticals, Inc. | 4 | $69 |
| Boehringer Ingelheim | 3 | $65 |
| AstraZeneca | 4 | $64 |
| Dexcom, Inc. | 3 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Ascensia Diabetes Care US Inc. | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Abbott | 2 | $49 |
| Novartis | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Lundbeck LLC | 1 | $26 |
| Medtronic | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Merck | 1 | $19 |
| Pfizer | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$125
How this compares
$2,438 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $44,068 |
| OzempicSemaglutide | 41 | $41,071 |
| JardianceEmpagliflozin | 26 | $33,650 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $13,916 |
| FarxigaDapagliflozin Propanediol | 11 | $13,781 |
| Bydureon BciseExenatide Microspheres | 12 | $9,277 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $7,411 |
| VascepaIcosapent Ethyl | 16 | $5,780 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $2,877 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 27 | $2,131 |
| Atorvastatin Calcium | 235 | $1,935 |
| Gabapentin | 128 | $1,664 |
| Potassium Chloride | 80 | $1,475 |
| PaxlovidNirmatrelvir/Ritonavir | 15 | $1,348 |
| Fluticasone Propionate | 101 | $1,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $19 | $45,41559 claims |
| Novo NordiskOzempic | $85 | $41,07141 claims |
| Boehringer IngelheimJardiance | $65 | $33,65026 claims |
| AstraZenecaFarxiga, Symbicort | $64 | $21,19328 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $59 | $13,91611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Sebring
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.